A Deeper Look into Immunotherapies in the Management of Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Improving Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

The Promise of Immunotherapy in the Management of Advanced Cutaneous Squamous Cell Carcinoma (CSCC): What Managed Care Needs to Know is a 3-part live webinar series that will provide attendees with the latest information in the management of CSCC

This is Part 1 of the series focusing on improving clinical and economic outcomes

This activity is an archive from the webinar held May 15, 2019

This activity is valid from June 1, 2019 to June 1, 2021


Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Regeneron Pharmaceuticals

Cutaneous squamous-cell carcinoma (cSCC) is the second-most common cancer of the skin, usually occurring in areas exposed to the sun. Sunlight exposure and immunosuppression are the main risk factors for cSCC, with chronic sun exposure being the strongest environmental risk factor. Approximately 2.2 million people have cSCC at any given time and it makes up around 20% of all skin cancer cases. While prognosis is usually good, if distant spread occurs five-year survival is approximately 34%. In 2016, it resulted in about 51,900 deaths globally. Current treatment response rates in patients with cSCC are suboptimal, with a minority of patients experiencing complete or partial response with present pharmacologic treatment options. Moreover, surgeries to remove tumors can be disfiguring, and elderly patients often are not candidates for chemotherapeutic agents because they cannot tolerate the toxicities.
Fortunately, novel immunotherapies including PD-1 inhibitors, have shown improved safety and efficacy for patients with metastatic disease. These treatments have recently become available and are providing clinicians alternative options to improve both outcomes and quality of life in patients with advanced cSCC.

Upon completion of this activity, participants will be able to:

  • Identify current unmet clinical needs in the management of advanced cutaneous squamous-cell carcinoma (cSCC) and evidence-based recommendations for the care of patients with these tumors

  • Examine the role of the PD-1 pathway and T-cell activity in the pathophysiology of cSCC

  • Analyze the efficacy and safety of recently approved and emerging immunotherapies in the management of advanced cSCC

  • Identify of patients with advanced cSCC who would potentially benefit from immunotherapies in advanced cSCC

  • Discuss individualized cSCC treatment strategies, taking into consideration risks and benefits of therapies, patient characteristics, patient quality of life, and patient preferencetients with severe asthma that include shared decision making and promoting treatment adherence

Faculty: Omid Hamid, MD
Chief of Research/Immuno-Oncology
The Angeles Clinic
Co-Director, Cutaneous Malignancy Program
Cedars Sinai


Dr. Hamid has provided contractual research for his institution for AstraZeneca, Bristol-Myers Squibb, Celldex, Genentech/Roche, Immunocore, Incyte, MedImmune, Merck, Merck Serono, Novartis, Pfizer, Roche, Amgen, CytomX, Iovance, Regeneron, and Polynoma. He served on an advisory board for Amgen, Bristol-Myers Squibb, Roche, Merck, and Novartis. He is on the speaker’s bureau for Amgen, Bristol-Myers Squibb, Genentech, Novartis and Sanofi/Regeneron. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Regeneron Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue